White Matter Hyperintensity Trajectories in Patients With Progressive and Stable Mild Cognitive Impairment
Citation Manager Formats
Make Comment
See Comments

Abstract
Background and Objectives: White matter hyperintensities are pathological brain changes that are associated with increased age and cognitive decline. However, the association of white matter hyperintensity burden with amyloid positivity and conversion to dementia in people with mild cognitive impairment (MCI) is unclear. The aim of the current study was to expand on this research by examining whether change in white matter hyperintensity burden over time differs in amyloid-negative (Aβ-) and amyloid-positive (Aβ+) people with MCI who either remain stable or convert to dementia. To examine this question, we compared regional white matter hyperintensity burden in four groups: amyloid positive (Aβ+) progressor, amyloid negative (Aβ–) progressor, amyloid positive (Aβ+) stable, and amyloid negative (Aβ–) stable.
Methods: Participants with MCI from the Alzheimer’s Disease Neuroimaging Initiative were included if they had APOE ɛ4 status and if amyloid measures were available to determine amyloid status (i.e., amyloid positive, or amyloid negative). Participants with a baseline diagnosis of MCI, had APOE ɛ4 information and amyloid measures were included. An average of 5.7 follow-up timepoints per participant were included, with a total of 5054 follow-up timepoints with a maximum follow-up duration of 13 years. Differences in total and regional white matter hyperintensity burden were examined using linear mixed-effects models.
Results: A total of 820 participants (55-90 years of age) were included in the study (Aß+ Progressor, n= 239; Aß– Progressor, n= 22; Aß+ Stable, n= 343; Aß– Stable, n= 216). People who were Aß– stable exhibited reduced baseline white matter hyperintensities compared to Aß+ progressors and Aß+ stable at all regions of interest (β belongs to [.20 –.33], CI belongs to [.03 –.49], p<.02), except Deep white matter hyperintensities. When examining longitudinal results, compared to Aß– stable, all groups had steeper accumulation in white matter hyperintensity burden with Aß+ progressors (β belongs to [-.03–.06], CI belongs to [-.05–.09], p<.01) having the largest increase (i.e., largest increase in white matter hyperintensity accumulation over time).
Discussion: These results indicate that white matter hyperintensity accumulation contributes to conversion to dementia in older adults with mild cognitive impairment who are amyloid-positive and negative people.
- Received December 22, 2022.
- Accepted in final form April 25, 2023.
- © 2023 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard
► Watch
Related Articles
- No related articles found.